Cardiac myocytes have been shown to express constitutively endothelial nitric oxide synthase (eNOS) (nitric oxide synthase 3), the activation of which has been implicated in the regulation of myocyte L-type voltagesensitive calcium channel current (I Ca-L ) and myocyte contractile responsiveness to parasympathetic nervous system signaling, although this implication remains controversial. Therefore, we examined the effect of the muscarinic cholinergic agonist carbachol ( The regulation of the beating rate and force of contraction of the heart by the autonomic nervous system has been one of the most intensively studied aspects of cardiovascular pharmacology. Recently, a number of studies have implicated an important role for nitric oxide (NO) generation in mediating some aspects of muscarinic cholinergic and adrenergic signaling, both in intact hearts and in isolated myocytes (1-12). NO, whether released by pharmacologic NO donors or generated by activation of endogenous NO synthases (NOS), has been shown to suppress the activation of voltage-sensitive Ca 2ϩ current (I Ca-L ) by ␤-adrenergic agonists (7-12). Conversely, inhibition of NO generation within cardiac myocytes, including specialized pacemaker and conduction system cells, has been shown to blunt the negative inotropic and chronotropic effects of parasympathetic nerve stimulation in the mammalian heart in situ when infused with a ␤-adrenergic agonist (3-6).
The regulation of the beating rate and force of contraction of the heart by the autonomic nervous system has been one of the most intensively studied aspects of cardiovascular pharmacology. Recently, a number of studies have implicated an important role for nitric oxide (NO) generation in mediating some aspects of muscarinic cholinergic and adrenergic signaling, both in intact hearts and in isolated myocytes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . NO, whether released by pharmacologic NO donors or generated by activation of endogenous NO synthases (NOS), has been shown to suppress the activation of voltage-sensitive Ca 2ϩ current (I Ca-L ) by ␤-adrenergic agonists (7) (8) (9) (10) (11) (12) . Conversely, inhibition of NO generation within cardiac myocytes, including specialized pacemaker and conduction system cells, has been shown to blunt the negative inotropic and chronotropic effects of parasympathetic nerve stimulation in the mammalian heart in situ when infused with a ␤-adrenergic agonist (3) (4) (5) (6) .
The enzyme responsible for the generation of NO within cardiac myocytes is the NOS originally described in endothelial cells (i.e., eNOS or NOS3). eNOS is a Ca 2ϩ -calmodulinactivated enzyme that is localized in both myocytes and endothelial cells to specialized plasmalemmal microdomains termed caveolae (15, 16) . A principal target of eNOSgenerated NO is the soluble guanylyl cyclase (17) (18) (19) (20) (21) . Indeed, agents that prevent cGMP generation have been shown to attenuate significantly the inhibitory effect of NO on I Ca-L (8) (9) (10) 17) .
Nevertheless, the importance of endogenous NO generation in the regulation of cardiac I Ca-L , particularly in response to muscarinic cholinergic agonists, remains controversial (see refs. 16, 21 , and 22 for reviews). In frog ventricular myocytes, for example, NOS inhibitors failed to modify cholinergic inhibition of I Ca-L (23) . Inhibition of a cAMP-stimulated chloride current by cholinergic agonists in guinea pig ventricular myocytes also was unaffected by NOS inhibitors (24) . This controversy prompted us to examine the control of I Ca-L by muscarinic cholinergic signaling in atrial and ventricular myocytes of mice with targeted disruption of eNOS (eNOS null ). We found that muscarinic cholinergic agonists significantly increased intracellular cGMP levels in wild-type (WT) but not eNOS null myocytes and that cholinergic inhibition of ␤-adrenergic agonist-stimulated I Ca-L and myocyte contractile amplitude both were impaired in myocytes lacking functional eNOS.
METHODS
Cell Isolation. Calcium-tolerant ventricular and atrial myocytes were isolated from mice as described (25) . eNOS null founder mice were backcrossed into their C57B͞6 and 129SvEv backgrounds from which both eNOS null and WT animals were obtained. In brief, hearts obtained from mice with targeted disruption of eNOS (eNOS null ) (26) or from age-matched WT animals were excised under ether anesthesia and retrogradely perfused with Hepes-buffered Tyrode's solution for 5 min, followed by perfusion with a nominally Ca 2ϩ -free Hepes-buffered Tyrode's solution for 5-10 min and an additional 10 min with the Ca 2ϩ -free Hepes-buffered Tyrode's solution containing 0.05% collagenase (Worthington). The great vessels, atria, and valvular tissues were removed, and ventricular muscle was gently minced in the same enzyme-containing solution plus trypsin (0.02 mg͞ml; Sigma). Myocytes then were dissociated and sedimented in 2% BSA. Cells were plated onto laminin-coated glass coverslips and were transferred to perfusion chambers mounted on the stage of an inverted microscope for measurements of whole-cell current and single-cell shortening.
Electrophysiological Experiments. Whole-cell I Ca-L was measured by using the membrane-ruptured patch configuration (27) . To facilitate I Ca-L measurement, K ϩ was replaced by Cs ϩ on either side of the membrane. The pipette solution contained 90 mM aspartic acid, 30 mM CsCl, 110 mM CsOH, 10 mM EGTA, 3 mM ATP-Mg 2ϩ , 3 mM Na 2 -phosphocreatine, 5 mM Hepes, and 1 mM CaCl 2 (pH 7.2) when it was titrated with CsOH. pCa 2ϩ was calculated to be in the range of 7.4-7.5 (28) . When measuring acetylcholine-sensitive K ϩ current, the pipette solution contained 110 mM potassium aspartate, 30 mM KCl, 10 mM EGTA, 1 mM CaCl 2 , 3 mM ATP-K, 2 mM ATP-Mg, 3 mM Na 2 -phosphocreatine, and 5 mM Hepes (pH 7.2) when it was titrated with KOH. Cells were perfused with Hepes-buffered solution containing 145 mM NaCl, 5.4 mM CsCl, 1.0 mM MgCl 2 , 1.0 mM Na 2 HPO 4 , 5.0 mM Hepes, 1 mM CaCl 2 , and 10 mM glucose; pH was adjusted to 7.4 with CsOH. A liquid junction potential of Ϫ10 mV was measured and was corrected electronically. The electrode direct current resistance was between 1 and 3 M⍀. Experiments were performed at 32.5°C. The temperature of the perfusion chamber was controlled by a Biowarmer MT-1 (Narishige, Japan). Holding potential was Ϫ80 mV. To inactivate the fast inward Na ϩ current and the T-type Ca 2ϩ current, a prepulse of 200-ms duration to Ϫ40 mV was applied first, and I Ca-L was activated by a further depolarization to 0 mV for 200 ms. I Ca-L was measured as the difference between the steadystate current level and the peak inward current at 0 mV. Data acquisition and storage were performed by using [smcap]pclamp software (version 5.51, Axon Instruments, Foster City, CA) interfaced with a computer and analyzed off-line. Membrane currents were digitized at 2.5 kHz. The recording chamber volume was 0.5 ml, and a constant flow rate of 1.5 ml͞min was used to superfuse the cells. A solenoid, drivercontrolled, fast perfusion apparatus was used to change among solutions containing various test agents.
Measurement of Myocyte Contractility. Myocyte contractile amplitude was measured as described (12) by using a video motion detector (Crescent Electronics, Sandy, UT). Cells were field-stimulated at 1.5ϫ the threshold at 1-3 Hz with a stimulator (Grass Instruments, Quincy, MA) that generates rectangular waves of 3-ms duration.
cGMP Assay. Basal and carbachol (CCh)-stimulated, intracellular cGMP production were determined by cGMP enzyme immunoassay. In brief, murine ventricular myocytes were used 2-3 h after plating. After removing the medium, cells were washed twice with Locke's buffer (154 mM NaCl͞5.6 mM KCl͞2.0 mM CaCl 2 ͞1.0 mM MgCl 2 ͞3.6 mM NaHCO 3 ͞5.6 mM glucose͞10 mM Hepes, pH 7.4). Cells then were equilibrated at 37°C for 30 min in Locke's buffer containing 1 mM 3-isobutyl-1-methylxanthine and 1 mM L-arginine or Lnitroarginine. Superoxide dismutase (100 units͞ml) was added after 25 min of equilibration. Myocytes were treated with 5 M CCh or 10 M 3-morpholino-sydnonimine (SIN-1) for 3 min at 37°C. The medium was removed rapidly, and the reaction was terminated with ice-cold 0.1 M HCl. After 20 min of incubation on ice, the cells were scraped, and the extracts were collected, were neutralized by NaOH, and were buffered with 2.5 M sodium acetate to pH 5.8. After centrifugation for 5 min at 14,000 ϫ g, cGMP levels in the supernatant were determined by using a kit according to the manufacturer's instructions (Cayman Chemicals, Ann Arbor, MI). Each experiment was performed in triplicate, and the results were calibrated against standard curves and were expressed as picomole per mg protein.
Reagents. Collagenase and DNase were purchased from Worthington. Trypsin, hyaluronidase, isoproterenol (ISO), carbamylcholine chloride, phenylmethanesulfonyl fluoride, and pepstatin were purchased from Sigma. N G -monomoethyl-L-arginine monoacetate was purchased from Alexis Biochemicals (San Diego).
Statistics. Statistical analyses were done by using Student's t test or ANOVA followed by the Bonferroni modification where appropriate.
RESULTS
To determine whether eNOS-dependent signaling pathways played a role in muscarinic cholinergic regulation of cardiac function, we first compared the inotropic response of ventricular myocytes isolated from either WT or eNOS null mice to the ␤-adrenergic agonist ISO alone and in combination with the cholinergic agonist CCh. The absence of a Ca 2ϩ -calmodulinregulated NOS was verified by the lack of detectable eNOS in ventricular muscle and isolated murine myocytes from eNOS- Table 1 , in which contractile amplitude is expressed as percentage changes in cell length. In 10 cells from four WT mice, myocyte shortening was increased by ISO from 9.2 to 17.5% of resting cell length, a response that could be diminished to 12.8% by CCh (P Ͻ 0.01). ISO-stimulated myocyte shortening was not significantly different in eNOS null myocytes (n ϭ 10) isolated from four age-matched animals from the appropriate (C57B͞6 ϫ 129 SvEv) background strains. However, unlike in WT cells, subsequent application of CCh did not result in a significant reduction in the amplitude of myocyte shortening (P Ͼ 0.1; Table 1 Because the signal transduction cascade linking M 2 muscarinic cholinergic receptor activation, eNOS, and control of I Ca-L is presumed to act via cGMP, we next examined cGMP levels in isolated myocytes and whole hearts removed from eNOS null and WT animals. As shown in Fig. 3 A and B , CCh significantly increased myocyte cGMP levels in WT myocytes and whole ventricular muscle slices, respectively, an effect that could be blocked by the NOS inhibitor L-nitroarginine. In contrast, CCh had no effect on cellular cGMP levels in eNOS null animals. To demonstrate that cGMP levels in myocytes from eNOS null animals could be elevated by NO, the pharmacologic NO donor SIN-1 was employed. As shown in Fig. 3 , SIN-1 markedly increased cGMP levels in both WT and eNOS null myocytes both in isolated myocytes (A) and in whole tissue slices (B). As expected, the muscarinic agonist-induced elevation of cGMP in WT myocytes could be suppressed by the guanylyl cyclase inhibitor 1H-[1,2,4])Oxadiazole-[4,3-a] quinoxalin-1-one (1 M).
In atrial muscle, muscarinic cholinergic stimulation is known to activate an acetylcholine-sensitive K ϩ current (I K(ACh) ), which hyperpolarizes the membrane and abbreviates action potential duration, an important regulatory mechanism for suppressing the chronotropic and inotropic responsiveness of the heart. To verify that activation of I K(ACh) by muscarinic agonists, which is not known to be linked to NOS activation, remained unaffected in eNOS null myocytes, we examined I K(ACh) in atrial and ventricular myocytes. Fig. 4A shows the current-voltage relationship of I K(ACh) generated by using a ramp protocol in an atrial myocyte isolated from an eNOS null mouse. In seven cells from two eNOS null mice, CCh (1 M) markedly and reversibly activated I K(ACh) . The amplitude of I K(ACh) measured at Ϫ100 mV was not significantly different from the current seen in WT atrial myocytes (Fig. 4B) . I K(ACh) also could be detected in ventricular myocytes from both WT and eNOS null hearts. Fig. 4C shows the activation of I K(ACh) in an eNOS null ventricular myocyte. Hyperpolarization from a holding potential of Ϫ40 mV to Ϫ100 mV activated the inwardly rectifying background K ϩ current. Exposure to CCh (1 M) significantly increased this current, which returned to control levels on removal of CCh. The current-voltage relationship of ventricular I K(ACh) is shown in Fig. 4D . The muscarinic cholinergic antagonist atropine (1 M) completely reversed the effect of CCh. When measured at a test potential of Ϫ100 mV, the magnitude of ventricular I K(ACh) did not differ between WT and eNOS null mice (Fig. 4E) . Because activation of I K(ACh) is known to shorten action potential duration, we verified that this could be demonstrated in eNOS Fig. 4F . This CCh-induced abbreviation in action potential duration was caused by the activation of muscarinic receptors because the action potential shortening could be reversed by atropine.
DISCUSSION
Three areas of controversy have been resolved in this study using the eNOS null mice. The first is the unequivocal demonstration that eNOS activation is essential for muscarinic cholinergic control of ventricular I Ca-L but not for the activation of I K(ACh) . Secondly, we have demonstrated that the stimulation of myocyte guanylyl cyclase and the increase in intracellular cGMP by muscarinic cholinergic agonists are dependent on the activation of myocyte eNOS. Although the effects of increased intracellular cGMP on I Ca-L in myocytes have been reported to range from stimulatory to neutral to inhibitory, depending on the specific species, myocyte phenotype, and level of intracellular cAMP, the data reported here support a growing consensus that cGMP suppresses the magnitude of Ca 2ϩ influx via I Ca-L in cells that have elevated cAMP levels (19, (29) (30) (31) (32) . A similar NO͞cGMP-dependent signal transduction pathway also has been demonstrated in cardiac pacemaker cells (33, 34) and basophilic cells (35) after exposure to adenosine. Finally, we have demonstrated that I K(ACh) is present within murine ventricular as well as atrial myocytes. Although the I K(ACh) current density was relatively low in ventricular myocytes, activation of I K(ACh) was able to shorten action potential duration in these cells.
The presence of I K(ACh) channels in ventricular cells may account in part for the demonstration of some NOindependent effects of muscarinic cholinergic agonists on myocyte contractile function (36) (37) (38) (39) (40) (41) (42) . Expression of I K(ACh) in ventricular muscle may explain why there was a trend for CCh to inhibit myocyte contractile responsiveness to ISO in eNOSnull mice. Indeed, in two eNOS null myocytes (cells 7 and 8 in Table 1 ), the extent of CCh-induced inhibition of contractile responsiveness was comparable to that seen in myocytes from WT mice. These differences in responsiveness to CCh in eNOS null myocytes may be in part caused by the known heterogeneity in expression levels of I K(ACh) in different regions of ventricular muscle (40, 43) . It also is possible that eNOS null ventricular myocytes might exhibit an increase in expression of I K(ACh) because increased expression of K ϩ channels has been reported recently in response to hypertrophic stimuli in vitro (44) . The hearts of eNOS null animals typically are hypertrophied moderately compared with WT hearts, presumably because of the sustained hypertension characteristic of this animal model (26) .
Regardless of the effects of limited expression of I K(ACh) in ventricular myocytes from eNOS null animals, the absence in eNOS null cells of an intact signal transduction cascade linking muscarinic cholinergic receptor activation to myocyte contractile responsiveness could be verified by measurement of intracellular cGMP levels and by whole-cell patch clamp measurements of I Ca-L . Of interest, data from our laboratory on isolated adult rat ventricular myocytes and by others on intact heart preparations have noted that NOS inhibition accentuates the contractile response to ISO even in the absence of a muscarinic agonist (2) . Although there was a trend toward an (Ϸ10%) increase in contractile amplitude in WT compared with eNOS null cells, this increase did not reach statistical significance in the number of cells studied here. This likely is caused in part by the fact that the previous report (2) used submaximal concentrations of ISO (e.g., 2 nM ISO in isolated adult rat ventricular myocytes), unlike the near maximal response elicited by 10 nM ISO in the experiments reported here.
Direct effects of pharmacologic NO donors on myocyte ion channel function also have been reported. Campbell et al. (45) and Hu et al. (46) noted that NO donors, and particularly S-nitrosothiols, can directly affect I Ca-L in ferret ventricular myocytes and in L-type Ca 2ϩ channel subunits transiently transfected into HEK293 cells, respectively. In neither report were these effects attributable to activation of guanylyl cyclase in these cells. Musialek et al. (47) also reported that the NO donors SIN-1 and sodium nitroprusside both had a concentration-dependent, biphasic effect on the hyperpolarizationactivated inward current I f in guinea pig sinoatrial node cells, an effect that was at least in part caused by activation of guanylyl cyclase. These and other reports (reviewed in refs. 16, 21, and 22) show that NO donors can have both cGMPdependent and cGMP-independent effects on I Ca-L , I f , and other ion channel components in cardiac myocytes and suggest additional mechanisms through which both endogenous and exogenous sources of NO could affect myocardial contractile function.
However, pharmacologic NO donors cannot mimic the spatial and temporal constraints on NO generated endogenously within cells, such as the targeting of eNOS in cardiac myocytes to sarcolemmal caveolae. The data presented here in eNOS null cardiac myocytes nevertheless support previous work using pharmacologic NOS inhibitors and͞or NO donors that implicate an important role for eNOS in mediating parasym- pathetic nervous system signaling in the heart (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . These data also support the contention that the effects of endogenously generated NO within cardiac myocytes are mediated by activation of guanylyl cyclase. Of importance, although the data presented here imply that regulation of I Ca-L is a major intracellular target of CCh-mediated eNOS activation, other mechanisms may be involved (e.g., an alteration in myofilament Ca 2ϩ sensitivity by regulation of cAMP-dependent or cGMP-dependent phosphorylation of, for example, troponin I). Finally, the detection of I K(ACh) in ventricular myocytes provides one explanation for the observation of some NOindependent effects of muscarinic cholinergic agonists on the contractile function of ventricular myocytes. 95 (1998) 
